Steven Cohen’s Mirum Pharmaceuticals MIRM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-346,991
Closed -$34.8M 4376
2026
Q1
$32.1M Buy
346,991
+156,353
+82% +$14.7M 0.04% 572
2025
Q4
$15.1M Sell
190,638
-600,037
-76% -$43.1M 0.02% 1092
2025
Q3
$58M Buy
790,675
+531,809
+205% +$33.8M 0.1% 235
2025
Q2
$13.2M Buy
258,866
+26,768
+12% +$1.19M 0.03% 636
2025
Q1
$10.5M Buy
+232,098
New +$10.9M 0.02% 668
2023
Q3
Sell
-601,038
Closed -$15.5M 2725
2023
Q2
$15.5M Buy
601,038
+43,600
+8% +$1.16M 0.05% 456
2023
Q1
$13.4M Buy
557,438
+217,928
+64% +$4.97M 0.04% 464
2022
Q4
$6.62M Buy
+339,510
New +$6.71M 0.02% 677
2022
Q2
Sell
-153,389
Closed -$3.38M 1540
2022
Q1
$3.38M Sell
153,389
-161,454
-51% -$3.29M 0.01% 782
2021
Q4
$5.02M Buy
314,843
+170,443
+118% +$2.65M 0.02% 667
2021
Q3
$2.88M Buy
144,400
+125,600
+668% +$2.04M 0.01% 747
2021
Q2
$325K Buy
18,800
+13,800
+276% +$247K ﹤0.01% 889
2021
Q1
$99K Buy
+5,000
New +$95.7K ﹤0.01% 906
2020
Q3
Sell
-97,415
Closed -$1.9M 1026
2020
Q2
$1.9M Buy
+97,415
New +$1.63M 0.01% 601

Other funds holding MIRM

Steven Cohen's MIRM Position: Q2 2026 in Review

Steven Cohen sold out of Mirum Pharmaceuticals (MIRM) in Q2 2026, closing a stake of 346,991 shares — an estimated $34.8M sold.

Steven Cohen first reported a position in MIRM in Q2 2020 and held it in 14 quarters. The position peaked at $58M in Q3 2025. 326 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Steven Cohen reported no remaining Mirum Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 346,991 Mirum Pharmaceuticals shares in Q2 2026, an estimated $34.8M.
  • Steven Cohen first reported a position in Mirum Pharmaceuticals in Q2 2020 and held it in 14 quarters.
  • Steven Cohen's Mirum Pharmaceuticals position peaked at $58M in Q3 2025.
  • 326 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.